Telo Genomics Cash Per Share vs. Current Valuation

TDSGF Stock  USD 0.07  0.01  13.58%   
Based on Telo Genomics' profitability indicators, Telo Genomics Corp may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Telo Genomics' ability to earn profits and add value for shareholders.
For Telo Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telo Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telo Genomics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telo Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telo Genomics Corp over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Telo Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telo Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telo Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Telo Genomics Corp Current Valuation vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Telo Genomics's current stock value. Our valuation model uses many indicators to compare Telo Genomics value to that of its competitors to determine the firm's financial worth.
Telo Genomics Corp is rated below average in cash per share category among its peers. It also is rated below average in current valuation category among its peers reporting about  274,649,440  of Current Valuation per Cash Per Share. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telo Genomics' earnings, one of the primary drivers of an investment's value.

Telo Current Valuation vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Telo Genomics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
0.05 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Telo Genomics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
13.73 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Telo Current Valuation vs Competition

Telo Genomics Corp is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 60.48 Billion. Telo Genomics adds roughly 13.73 Million in current valuation claiming only tiny portion of equities under Health Care industry.

Telo Genomics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Telo Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Telo Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Telo Genomics' change in net profit over the period of time. It can combine multiple indicators of Telo Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada. TELO GENOMICS is traded on OTC Exchange in the United States.

Telo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Telo Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Telo Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Telo Genomics' important profitability drivers and their relationship over time.

Use Telo Genomics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telo Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telo Genomics will appreciate offsetting losses from the drop in the long position's value.

Telo Genomics Pair Trading

Telo Genomics Corp Pair Trading Analysis

The ability to find closely correlated positions to Telo Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telo Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telo Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telo Genomics Corp to buy it.
The correlation of Telo Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telo Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telo Genomics Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telo Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Telo Genomics position

In addition to having Telo Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Robots And Drones Thematic Idea Now

Robots And Drones
Robots And Drones Theme
Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years. The Robots And Drones theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Robots And Drones Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Telo OTC Stock

To fully project Telo Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Telo Genomics Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Telo Genomics' income statement, its balance sheet, and the statement of cash flows.
Potential Telo Genomics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Telo Genomics investors may work on each financial statement separately, they are all related. The changes in Telo Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Telo Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.